This study presents the first successful use of a peptidic vector, DOTATOC, labelled with the β-emitting radioisotope yttrium-90, for the treatment of a patient with somatostatin receptor-positive abdominal metastases of a neuroendocrine carcinoma of unknown localization. Tumour response and symptomatic relief were achieved. In addition, the new substance DOTA-TOC was labelled with the diagnostic chemical analogue indium-111 and studied in three patients with histopathologically verified neuroendocrine abdominal tumours for its diagnostic sensitivity and compared with the commercially available OctreoScan. In all patients the kidney-to-tumour uptake ratio (in counts per pixel) was on average 1.9-fold lower with111In-DOTATOC than with OctreoScan. DOTATOC could be a potential new diagnostic and therapeutic agent in the management of neuroendocrine tumours.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Krenning EP, Bakker WH, Breeman WAP, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin.Lancet 1989; 1: 242–244.
Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumours.N Engl J Med 1990; 323: 1246–1249.
Sivolapenko GB, Douli V, Pectasides D, et al. Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody.Lancet 1995; 346: 1662–1666.
About this article
Cite this article
Otte, A., Jermann, E., Behe, M. et al. DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 24, 792–795 (1997). https://doi.org/10.1007/BF00879669
- Somatostatin receptor-mediated internal radiotherapy
- DTPA-d-Phe1-octreotide (OctreoScan)
- DOTA-d-Phe1-Tyr3-octreotide (DOTATOC)